M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech BioSpaceEli Lilly plans to use BioArctic's technology to shuttle an undisclosed drug candidate into the brain.NeuroscienceRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) BioSpace Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Boehringer advances duo for aggressive cancers into phase 3Next: AbbVie climbs post-Allergan M&A peak with Apogee buy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
